Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. / Fosbøl, Marie Øbro; Petersen, Peter Meidahl; Daugaard, Gedske; Holm, Søren; Kjaer, Andreas; Mortensen, Jann.

I: Annals of Nuclear Medicine, Bind 32, Nr. 1, 01.2018, s. 16-21.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Fosbøl, MØ, Petersen, PM, Daugaard, G, Holm, S, Kjaer, A & Mortensen, J 2018, 'Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients', Annals of Nuclear Medicine, bind 32, nr. 1, s. 16-21. https://doi.org/10.1007/s12149-017-1212-1

APA

Fosbøl, M. Ø., Petersen, P. M., Daugaard, G., Holm, S., Kjaer, A., & Mortensen, J. (2018). Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Annals of Nuclear Medicine, 32(1), 16-21. https://doi.org/10.1007/s12149-017-1212-1

Vancouver

Fosbøl MØ, Petersen PM, Daugaard G, Holm S, Kjaer A, Mortensen J. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Annals of Nuclear Medicine. 2018 jan.;32(1):16-21. https://doi.org/10.1007/s12149-017-1212-1

Author

Fosbøl, Marie Øbro ; Petersen, Peter Meidahl ; Daugaard, Gedske ; Holm, Søren ; Kjaer, Andreas ; Mortensen, Jann. / Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. I: Annals of Nuclear Medicine. 2018 ; Bind 32, Nr. 1. s. 16-21.

Bibtex

@article{776b3e5fe9154123b4679cf94eeeea8d,
title = "Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients",
abstract = "BACKGROUND: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporary shortage of Ra-223 occurred for 2 months due to production irregularities. The aim of this study was to assess whether prolonged interval between Ra-223 cycles to non-disease related causes had a negative impact on clinical outcome of therapy.MATERIALS AND METHODS: Retrospective single-center study of mCRPC patients who initiated Ra-223 therapy in the period from March 2014 to February 2015. End points were number of completed Ra-223 cycles, overall survival (OS) and radiographic progression-free survival (rPFS). Bone scintigraphy, CT of thorax and abdomen, hematological status, PSA and alkaline phosphatase were evaluated prior to first dose and after 3rd and 6th treatment, respectively. Follow-up period was 18 months after first Ra-223 cycle.RESULTS: A total of 50 consecutive patients initiated Ra-223 therapy in the time period. Seventeen of 50 patients (34%) had prolonged interval between cycles due to delivery problems. Median delay was 4 weeks (range 3-9 weeks). Patients with delayed treatment had significantly longer median rPFS [delayed patients: 7.1 months (95% CI 4.9-9.3) vs. 4.5 months (95% CI 2.8-6.3)]. There was no significant difference in number of completed cycles or median OS.CONCLUSION: We find no negative impact of prolonged interval between Ra-223 cycles due to non-disease related reasons on OS, rPFS or number of completed treatment cycles.",
keywords = "Journal Article",
author = "Fosb{\o}l, {Marie {\O}bro} and Petersen, {Peter Meidahl} and Gedske Daugaard and S{\o}ren Holm and Andreas Kjaer and Jann Mortensen",
year = "2018",
month = jan,
doi = "10.1007/s12149-017-1212-1",
language = "English",
volume = "32",
pages = "16--21",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients

AU - Fosbøl, Marie Øbro

AU - Petersen, Peter Meidahl

AU - Daugaard, Gedske

AU - Holm, Søren

AU - Kjaer, Andreas

AU - Mortensen, Jann

PY - 2018/1

Y1 - 2018/1

N2 - BACKGROUND: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporary shortage of Ra-223 occurred for 2 months due to production irregularities. The aim of this study was to assess whether prolonged interval between Ra-223 cycles to non-disease related causes had a negative impact on clinical outcome of therapy.MATERIALS AND METHODS: Retrospective single-center study of mCRPC patients who initiated Ra-223 therapy in the period from March 2014 to February 2015. End points were number of completed Ra-223 cycles, overall survival (OS) and radiographic progression-free survival (rPFS). Bone scintigraphy, CT of thorax and abdomen, hematological status, PSA and alkaline phosphatase were evaluated prior to first dose and after 3rd and 6th treatment, respectively. Follow-up period was 18 months after first Ra-223 cycle.RESULTS: A total of 50 consecutive patients initiated Ra-223 therapy in the time period. Seventeen of 50 patients (34%) had prolonged interval between cycles due to delivery problems. Median delay was 4 weeks (range 3-9 weeks). Patients with delayed treatment had significantly longer median rPFS [delayed patients: 7.1 months (95% CI 4.9-9.3) vs. 4.5 months (95% CI 2.8-6.3)]. There was no significant difference in number of completed cycles or median OS.CONCLUSION: We find no negative impact of prolonged interval between Ra-223 cycles due to non-disease related reasons on OS, rPFS or number of completed treatment cycles.

AB - BACKGROUND: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporary shortage of Ra-223 occurred for 2 months due to production irregularities. The aim of this study was to assess whether prolonged interval between Ra-223 cycles to non-disease related causes had a negative impact on clinical outcome of therapy.MATERIALS AND METHODS: Retrospective single-center study of mCRPC patients who initiated Ra-223 therapy in the period from March 2014 to February 2015. End points were number of completed Ra-223 cycles, overall survival (OS) and radiographic progression-free survival (rPFS). Bone scintigraphy, CT of thorax and abdomen, hematological status, PSA and alkaline phosphatase were evaluated prior to first dose and after 3rd and 6th treatment, respectively. Follow-up period was 18 months after first Ra-223 cycle.RESULTS: A total of 50 consecutive patients initiated Ra-223 therapy in the time period. Seventeen of 50 patients (34%) had prolonged interval between cycles due to delivery problems. Median delay was 4 weeks (range 3-9 weeks). Patients with delayed treatment had significantly longer median rPFS [delayed patients: 7.1 months (95% CI 4.9-9.3) vs. 4.5 months (95% CI 2.8-6.3)]. There was no significant difference in number of completed cycles or median OS.CONCLUSION: We find no negative impact of prolonged interval between Ra-223 cycles due to non-disease related reasons on OS, rPFS or number of completed treatment cycles.

KW - Journal Article

U2 - 10.1007/s12149-017-1212-1

DO - 10.1007/s12149-017-1212-1

M3 - Journal article

C2 - 28975586

VL - 32

SP - 16

EP - 21

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 1

ER -

ID: 189664184